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Background: In Spain, hospital medicines are assessed and selected by local Pharmacy and 
Therapeutics committees (PTCs). Of all the drugs assessed, cancer drugs are particularly 
important because of their budgetary impact and the sometimes arguable added value with 
respect to existing alternatives. This study analyzed the PTC drug selection process and the 
main objective was to evaluate the degree of compliance of prescriptions for oncology drugs 
with their criteria for use.
Methods: This was a retrospective observational study (May 2007 to April 2010) of PTC-
assessed drugs. The variables measured to describe the committee’s activity were number of 
drugs assessed per year and number of drugs included in any of these settings: without restric-
tions, with criteria for use, and not included in formulary. These drugs were also analyzed by 
therapeutic group. To assess the degree of compliance of prescriptions, a score was calculated 
to determine whether prescriptions for bevacizumab, cetuximab, trastuzumab, and bortezomib 
were issued in accordance with PTC drug use criteria.
Results: The PTC received requests for inclusion of 40 drugs, of which 32 were included in 
the hospital formulary (80.0%). Criteria for use were established for 28 (87.5%) of the drugs 
included. In total, 293 patients were treated with the four cancer drugs in eight different thera-
peutic indications. The average prescription compliance scores were as follows: bevacizumab, 
83% for metastatic colorectal cancer, 100% for metastatic breast cancer, and 82.3% for non-
small-cell lung cancer; cetuximab, 62.0% for colorectal cancer and 50% for head and neck 
cancer; trastuzumab, 95.1% for early breast cancer and 82.4% for metastatic breast cancer; and 
bortezomib, 63.7% for multiple myeloma.
Conclusion: The degree of compliance with criteria for use of cancer drugs was reasonably 
high. PTC functions need to be changed so that they can carry out more innovative tasks, such 
as monitoring conditions for drug use.
Keywords: decision-making, drug selection, drug utilization, formulary, neoplasm, Pharmacy 
and Therapeutics committee
Introduction
The ongoing inclusion of new medications in hospital formularies is a key factor 
explaining the increase in health care spending;1,2 however, new medications do not 
always result in better health outcomes,3 with very few actually offering significant 
advantages over existing therapies in terms of efficacy and safety. For example, a study 
published in the French independent journal Prescrire International found that in the 
5 years leading up to 2012, no new drugs licensed represented a significant advance for 
patients, and of 82 new drugs evaluated in 2012, only one represented a real advance 
and three offered an advantage.4





In the European Union, the procedure for authorizing 
the sale of new drugs does not require a comparison with 
standard treatments, so companies need only to prove that 
the risk–benefit balance of a new drug is favorable.5 Further, 
the procedure does not include a review of a drug’s cost-
effectiveness or place in therapy.6
It is therefore necessary to carry out these analyses in 
an additional study. Most of the drugs available in Spain are 
funded by the public health service and there is no national 
government agency, such as the National Institute for Health 
and Care Excellence in the UK, which carries out a central-
ized evaluation and makes decisions about funding.7
The Spanish National Health Service has a decentralized 
structure whereby autonomous regions make their own deci-
sions about health care spending and manage their budgets 
through their regional ministries of health. There are centers 
that evaluate new drugs, but they merely provide recom-
mendations, which hospitals and prescribers are in no way 
obliged to follow.
So neither the national nor the regional health ministries 
set out shared guidelines to rationalize the use of medicines 
in the Spanish National Health Service based on criteria 
relating to effectiveness, appropriate use, and efficiency. 
Drugs are therefore assessed and selected locally. In recent 
years, regional health ministries have published new legis-
lation to carry out baseline assessments for their regions, 
and some of them have established centralized PTCs that 
take some decisions mandatory for the whole region. 
Also, the Ministry of Health is currently in the process of 
conducting a cooperative national initiative project assess-
ing comparative efficacy and safety and introducing use 
criteria for new drugs or existing drugs seeking approval 
for new indications.
Drugs used in hospitals (those administered to inpatients 
and outpatients attending the hospital for drug administration, 
and drugs that can only be dispensed by the hospital phar-
macy service) are assessed by Pharmacy and Therapeutics 
committees (PTCs). These committees select the drugs to 
be used, generally taking into account pharmacoeconomic 
criteria and the relative efficiency of drugs compared with the 
alternatives available. The drugs that are selected are added 
to the formulary for each hospital.8
Once a drug has been selected, the PTC may establish 
conditions for its use so that the drug is only used in sub-
groups of patients where it will have clinically significant 
benefits and where the cost has been taken into account. Use 
of the drug must then be monitored to ensure that it meets 
the established criteria.
Of all the drugs assessed by PTCs, cancer drugs are 
particularly important because of their budgetary impact9,10 
and their sometimes arguable added value with respect to 
existing alternatives, which is measured in terms of improved 
rates of survival or quality of life.11
To date, no studies have been published that monitor 
the real conditions of use of oncology drugs in Spanish 
National Health Service hospitals or that ascertain whether 
they are used in accordance with the PTC criteria set out by 
the hospital.
The aims of this study were to analyze the selection of 
new drugs by the PTC of a large secondary care hospital 
in Spain and to assess the degree to which the cancer 
drugs included in the hospital’s formulary were used in 
accordance with the criteria for use set out by the PTC 
(compliance).
Materials and methods
study design and setting
A retrospective observational longitudinal study was car-
ried out between May 1, 2007 and April 30, 2010 in the 
setting of Cabueñes Hospital, a Spanish National Health 
Service general secondary care hospital. The hospital serves 
a population of 303,038 in the Spanish region of Asturias. 
Oncology treatments for the whole area are administered at 
this hospital. The PTC of Cabueñes Hospital was created in 
1974. It is a multidisciplinary committee made up of physi-
cians, pharmacists, and nurses, as well as members of the 
hospital’s management team. At the request of clinicians, the 
PTC assesses drugs for inclusion in the hospital formulary 
using the methodology proposed by the Group for Innovation, 
Assessment, Standardization and Research in the Selection 
of Drugs (GENESIS) of the Spanish Society of Hospital 
Pharmacy.12 The PTC can make one of three decisions for 
each drug: not included, included without criteria for use, 
and included with criteria for use.
Drug selection by the PTC
The study examined the selection of all new drugs assessed 
by the PTC during the study period. Drugs were selected 
for inclusion in the study by consulting the minutes of the 
PTC meetings.
Two main variables were collected in order to evalu-
ate the selection activities of the PTC, ie, number of drugs 
assessed per year and number of drugs included in any of 
these settings: without restrictions, with criteria for use, and 
not included in formulary. The drugs were also analyzed by 
therapeutic group.




From drug use criteria to clinical practice
Compliance with drug inclusion criteria
All oncology drugs approved by the PTC were included in the 
study. The drugs were bevacizumab, cetuximab, trastuzumab, 
and bortezomib, and their use was assessed from the time 
each one was approved by the PTC (bevacizumab May 20, 
2008; cetuximab March 18, 2008; trastuzumab February 19, 
2008; and bortezomib July 17, 2007).
Patients treated with any of the four cancer drugs (beva-
cizumab, cetuximab, trastuzumab, and bortezomib) were 
identified by consulting the pharmacy service database for 
the prescription, validation, and preparation of cytostatic 
drugs. Any other information required was retrieved from 
patients’ notes. Patients taking part in a clinical trial and those 
taking any of the drugs for an off-label purpose as current 
national regulations lay down or for indications other than 
the treatment of cancer were excluded from the study. When 
a patient had used a drug for two different episodes, he or 
she was considered to be two respective patients. Identifying 
information was removed from patient records to maintain 
confidentiality; thus, approved of an investigational review 
board was not required.
In order to assess the degree to which prescriptions 
complied with the criteria for use stipulated by the PTC, 
the actual conditions under which each drug was being 
used were compared with the PTC’s criteria for use. 
Compliance was analyzed based on a series of variables 
for each drug: diagnosis (tumor location) and compliance 
with criteria for use in terms of stage of the disease, life 
expectancy, treatment regimen (in combination with other 
drugs), line of treatment (preferred order for treatment 
options available), previous treatments, duration of treat-
ment, and presence of certain gene mutations. When a drug 
was not used for the approved diagnosis (used off-label 
without asking for permission to use it, or for an indica-
tion not approved by the PTC), the rest of the variables 
were not assessed.
For each of the four drugs and for each of the clinical 
indications, a score was calculated using previous criteria-
for-use variables. Each criterion had the same weighting 
and could be assigned one of two values: yes (=1) or no 
(=0). The final score for each drug and clinical indication 
was determined by calculating the sum of the scores for 
the criteria-for-use variables, expressed as a percentage 
(Table 1). This score represented compliance with the PTC 
criteria for use. This scoring system has been previously used 
by García Robredo et al.13 The number and percentage of 
patients meeting all of the criteria were calculated for each 
drug and indication.
statistical analysis
Data on drug selection by the PTC were summarized in a 
frequency and percentage table. In order to assess the degree 
of compliance for each drug and indication, the average 
compliance percentage was calculated for each criterion for 
the group of patients treated in each case. The percentage of 
patients meeting all of the criteria for each drug and indication 
was calculated. The 95% confidence interval (CI) was com-
puted. Both of these summarized measures were illustrated 
in bar graphs. The analysis was carried out and graphs were 
created using statistics program R (version 3.0.1, R Founda-
tion for Statistical Computing, Vienna, Austria).14
Results
Drug selection by the PTC
Between May 2007 and April 2010, the PTC received 
requests for inclusion of 40 drugs in the hospital formulary 
(17 in the first year, eleven in the second, and 12 in the third), 
of which 32 were included (80.0%). Criteria for use were 
established for 28 (87.5%) of the drugs included. The four 
drugs included without criteria for use were assessed during 
the first year of the study.
By therapeutic group, the highest percentages of requests 
were for the Anatomical Therapeutic Chemical classification 
system15 group L (antineoplastic and immunomodulation 
agents), with seven requests, and group J (anti-infective 
agents for systemic use), also with seven requests, followed 
by group M (musculoskeletal system), with five requests. Of 
the eight drugs not included in the formulary, four were in 
group M. All of the drugs in groups L and J were included 
with criteria for use (Table 2).
Compliance with drug use
The baseline characteristics of all patients are shown in 
Table 3. The degree of compliance for the four drugs with cri-
teria for use defined by the PTC is described in Figure 1.
Bevacizumab
Bevacizumab was used in 114 patients. For 112 (98.2%), 
it was used for the following PTC-approved indications: 
 colorectal cancer in 57 patients (50.0%), breast cancer in 
seven patients (6.1%), and lung cancer in 48 patients (42.1%). 
It was also used in two patients with renal cancer, an indi-
cation that is approved in the drug’s summary of product 
characteristics but was not approved by the PTC.
All of the patients who were prescribed bevacizumab for 
metastatic colorectal cancer (n=57) were assumed to have a life 
expectancy of more than 3 months. In nine patients, it was not 





used concomitantly with capecitabine +  oxaliplatin, and in 20 it 
was not used as a first-line treatment, so the average compliance 
score for this indication was 83% (95% CI, 76.4%–89.5%). In 
the case of metastatic breast cancer, bevacizumab met all of the 
criteria for use and scored 100% for compliance. The degree of 
compliance in non-small-cell lung cancer was 82.3% (95% CI, 
78.4%–85.5%) because, although in all cases it was prescribed 
to patients without hemoptysis and with non-squamous cancer 
and to just one patient with brain metastasis, in nine patients it 
was not used as a first-line treatment, in eleven it was used in 
stages earlier than those approved, and in 30 of the 48 patients 
it was used in a chemotherapy regimen other than cisplatin + 
gemcitabine.
Cetuximab
During the study period, 35 patients started treatment with 
cetuximab, of whom 25 (71.4%) had colorectal cancer and 
ten (28.6%) had head and neck cancer. Therefore, 100% of 
prescriptions for cetuximab were for diseases included in the 
criteria for use set out by the PTC.
The compliance score for colorectal cancer was 62% 
(95% CI, 55.6%–68.4%). None of the patients with 
this type of cancer underwent epidermal growth factor 
receptor (EGFR) expression testing, all but two had 
metastases, and all but two had previously undergone 
chemotherapy with oxaliplatin or irinotecan. Cetuximab 
was administered in combination with irinotecan in 16 
of the 25 patients.
In the case of head and neck cancer, only one of the 
ten patients was not taking cetuximab concomitantly with 
radiotherapy. All but one of the patients could have undergone 
treatment with cisplatin, but instead received cetuximab in 
combination with paclitaxel; this reduced the compliance 
score to 50% (95% CI, 35.4%–64.6%).
Table 1 indicator calculations
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treatment with cisplatinc
Trastuzumab
early breast cancer C1.6 
heR2 3+
C2.6 
after: surgery, adjuvant  
or neoadjuvant  
chemotherapy or  
radiotherapy
C3.6 
Carboplatin +  





Metastatic breast cancer C1.7 
heR2 3+
C2.7 
Monotherapy, with  
docetaxel or paclitaxel  
or aromatase inhibitor
Bortezomib




Notes: aeach indication for each drug is designated a code, which is further subdivided according to the criteria set out by the Cabueñes hospital Pharmacy and Therapeutics 
Committee. For each criterion, a score (yes =1; no =0) is given; scores are totaled to calculate the compliance with Pharmacy and Therapeutics committee criteria; bKarnofsky 
score $5033 was used to determine life expectancy .3 months; cpatients who had a history of renal failure, hearing problems, or cardiovascular disease were considered 
ineligible for treatment with cisplatin.
Abbreviations: egFR, epidermal growth factor receptor; heR2, human epidermal growth factor receptor 2; XelOX, capecitabine + oxaliplatin.




From drug use criteria to clinical practice
Trastuzumab
Trastuzumab was used in 80 patients, but in two cases (2.5%) 
the drug was used in nonapproved indications (stomach can-
cer and sweat gland cancer). The highest compliance score 
was for early breast cancer (95.1%; 95% CI, 92.1%–98.2%), 
because all of the criteria were met in all but eight patients 
who were on a regimen other than carboplatin + docetaxel + 
trastuzumab. Thirteen of the 37 patients with metastatic 
breast cancer were using trastuzumab in an unapproved 
chemotherapy regimen, resulting in a final compliance score 
for this indication of 82.4% (95% CI, 74.3%–90.2%).
Bortezomib
Bortezomib was used in 64 patients, but in two cases the drug 
was used for indications not approved by the PTC (mantle 
cell lymphoma and Waldenström’s macroglobulinemia). Of 
the 62 patients undergoing treatment with bortezomib for 
multiple myeloma, it was used as a second-line or subsequent 
treatment in only 39. In one of these patients, the later lines 
of treatment were not administered as a result of relapse or 
resistance but because of side effects, which meant the previ-
ous line had to be stopped. The final compliance score was 
therefore 63.7% (95% CI, 51.6%–75.7%).
Discussion
The percentage of requested drugs that were included in 
the hospital formulary was similar to that found in previous 
national studies.16 This may be because of the tendency in 
Spain to standardize assessment methodologies, as encour-
aged by the Group for Innovation, Assessment, Standardiza-
tion and Research in the Selection of Drugs.17 This means 
that different hospitals and PTCs may use similar selection 
systems and procedures.
The number of drugs assessed decreased in the second and 
third years of the study because the PTC was not operational 
in 2006. This meant that extra effort was made in 2007 to 
assess the drugs requested during the committee’s period of 
inactivity. All of the oncologic drugs were assessed during 
Table 2 Drugs requested for inclusion in hospital formulary





With criteria for use 
n=28 (87.5%)
Without criteria for use 
n=4 (12.5%)
May 2007 to april 2008 eplerenone (C03Da) glutamine (B05XB) Clonidine (C02aC)
Botulinum toxin type B (M03aX) Bortezomib (l01XX)b levetiracetam (n03aX)
Bemiparin (B01aB) entecavir (J05aF) Olanzapine (n05ah)







May 2008 to april 2009 ibandronic acid (M05Ba) Fosfomycin-trometamol (J01XX)










May 2009 to april 2010 levobupivacaine (n01BB) natalizumab (l04aa)
Purified botulinum toxin type A (M03AX) Sulpur hexafluoride (V08DA)







Notes: aDrug codes according to the Anatomical Therapeutic Chemical classification system. bDrugs that were considered in the current study.





this first year as a need to give priority to cancer treatments 
over other drugs for less serious illnesses. The number of 
drugs assessed in the subsequent 2 years is consistent with 
the findings of other studies, and contrasts with the high 
number of drugs on the market.18–21  According to Puigventós 
Latorre et al,22 this could be because the request, assess-
ment, and approval process limits the number of drugs 
that can be assessed, so priority is given to those that could 
offer significant advances. This would also explain the high 
approval rate.
The high percentage of drugs included with criteria for 
use in this study also illustrates how the function of the 
PTC has evolved to perform more innovative tasks, such as 
establishing conditions for drug use. Further development of 
the process needs to include monitoring of drug use, drug 
switching protocols, indirect comparisons, and drawing up 
protocols or clinical guidelines.23,24
With regard to compliance, the highest compliance scores 
were for bevacizumab and trastuzumab, possibly because 
they are used in more prevalent cancers (breast, colorectal, 
and lung cancers)25 that incur higher costs, so budgetary 
 protocols are more likely to exist and be adhered to for these 
cancers.
The top compliance score was for bevacizumab in the 
treatment of metastatic breast cancer. Interestingly, in 2011, 
the US Food and Drug Administration26 withdrew this 
indication, which had been approved in 2008 as part of its 
accelerated approval program, because subsequent studies 
showed that progression-free survival was lower than initially 
calculated and with significant adverse effects; therefore, 
the benefits of treatment no longer outweighed the risks. In 
2010, the European Medicines Agency withdrew its indica-
tion combined with docetaxel, but kept the combination with 
paclitaxel and later added the indication for first-line treat-
ment in combination with capecitabine for patients in whom 
treatment with taxanes or anthracyclines was not considered 
appropriate.27
The average compliance score for cetuximab in patients 
with colorectal cancer was 62.0%. This relatively low score 
was because none of the patients met the EGFR expression 
criterion; this test is no longer performed for this tumor type 
following reports from various studies that the presence of 































Patients n (%) 62 (21.6) 10 (3.5) 25 (8.7) 41 (14.3) 37 (12.9) 48 (16.7) 57 (19.9) 7 (2.4)
age mean (sD) 67.7 (8.9) 57.3 (9.3) 61.9 (12.2) 55.7 (11.1) 60.3 (12.6) 60.8 (8.0) 62.6 (9.6) 60.4 (12.4)
Sex
Male n (%) 37 (59.7) 8 (80.0) 17 (68.0) 0 (0.0) 1 (2.7) 39 (81.2) 33 (57.9) 0 (0.0)






iiB 5 1 1
iii 3 2 1
iiia  11 9 1
iiiB 4 11 1






0 7 11 38 14 30 34 3
1 3 10 1 12 16 23 4
2 2 1 10 1
Unknown 2 1 1 1
Abbreviations: iss, international staging system; Ps, performance status (no data collected for multiple myeloma); eCOg, eastern Cooperative Oncology group.




From drug use criteria to clinical practice
the EGFR mutation does not determine cetuximab activity.28 
After the drug was approved by the PTC, the European 
Medicines Agency29 changed the indication to EGFR- positive 
patients with the wild-type KRAS gene. This is a good 
example of why PTC criteria need to be regularly reviewed 
and amended where appropriate. The lowest compliance 
score was for cetuximab in head and neck cancer (50.0%), 
where all but one of the patients could have received cispla-
tin, but an unapproved regimen (paclitaxel + cetuximab) was 
used instead. This is important because one of the ways to 
make cancer treatments more affordable is to monitor and 
reduce off-label use, which is used sometimes, according 
to Sullivan et al,30 in scenarios where there is little benefit 
and more toxicity compared with drugs that cost much less. 
If the compliance results had been assessed as the percent-
age of patients meeting all criteria defined by the PTC, the 
result would have been much lower, especially in the case 































































































































































































































































 lung cancer (n=48)
Cetuximab in colorectal
cancer (n=25)
Figure 1 indicator scores for the degree of compliance of prescriptions for cancer drugs with criteria for use.
Notes: The black horizontal line shows the percentage of patients who fulfilled all the criteria. “Mean” refers to the mean score for patients treated with each drug in each 
clinical indication based on the scores in compliance with Cabueñes hospital Pharmacy and Therapeutics Committee criteria. 





that patients needed to have relapsed or be resistant to at 
least one treatment. In August 2008, the European Medicines 
Agency authorized a new indication for previously untreated 
patients not eligible for high-dose chemotherapy with bone 
marrow transplant.31
The new indications approved by regulatory agencies 
after drugs are included in formularies show that drugs need 
to be reassessed by the PTC, and if appropriate, their criteria 
for use amended. The PTC should also carry out studies 
on the way in which approved drugs are used, in order to 
measure the degree of compliance with criteria for use, as 
recommended in the American Society of Health-System 
Pharmacists guidelines.32
The foremost limitation of the current study is that the 
results were interpreted retrospectively. A second limitation 
was  the small number of patients with some low-prevalence 
cancers that could only have been resolved by increasing the 
length of the study period, as all of the patients treated after a 
drug was included in the formulary were included in the study. 
However, the 3-year study period was the maximum length at 
the time the study began because, as mentioned above, the PTC 
was inoperative for a year and when it became active again 
new working guidelines were established. Third, the results are 
limited because the study was done in one center and with very 
specific drugs. If the study had been done in another setting 
with other drugs, the results could have been different, which 
compromises the external validity of the study.
The Spanish reimbursement process is changing, and the 
new process intends to rationalize, standardize, and expedite 
the assessment of new drugs. This study was conducted 
some years ago, so it would be interesting to do it again to 
see if the results would be similar nowadays.
Conclusion
The degree of compliance with criteria for use of cancer 
drugs is reasonably high. PTCs need to regularly review 
their criteria for use of individual drugs in light of clinical 
guidelines and newly approved indications. PTCs also need 
to continue to evolve and adapt their activities with regard to 
drug assessment, monitoring, and development of protocols. 
Further research should be carried out to investigate the 
clinical and financial benefits of establishing criteria for use 
as part of the drug selection process.
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